Published in Medicine and Law Weekly, June 1st, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Medtronic.
Report 1: Medtronic, Inc. (NYSE: MDT) today announced that it has received regulatory approval from the U.S. Food and Drug Administration (FDA) to begin marketing INFUSE(R) Bone Graft for certain oral maxillofacial and dental regenerative bone grafting procedures. This will be the third Pre-Market Approval (PMA) Application receiving FDA approval since 2002 for the INFUSE Bone Graft technology.
It is estimated that more than 350,000 bone grafting procedures to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.